Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sinew Pharma Inc (6634) Fair Value & Analysis

Healthcare · TW · Market cap 3.9B TWD

Price59.90 TWD
Fair Value45.92 TWD
Upside-23.3%
Quality95/100
Evidence: Low Range 34.44 TWD – 57.40 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Sinew Pharma Inc (6634) currently trades at 59.90 TWD, while our model-based Fair Value estimate is 45.92 TWD — implying the stock looks roughly 23.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Sinew Pharma Inc (6634) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 45.92 TWD versus a price of 59.90 TWD — about −23% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6634?
Our 21-model fair value for Sinew Pharma Inc is 45.92 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 59.90 TWD.
What is the quality score of 6634?
Sinew Pharma Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.